作者：张浩，贾志毅，李文静，田晓晨，刘玉胜，邝江莹，鹿庆华

单位：

1.山东大学第二医院心血管内科2.山东省济南市第四人民医院心血管内科

Units：

1.Department of Cardiology, the Second Hospital of Shandong University, Jinan 250033, China 2.Department of Cardiology, the Fourth People's Hospital of Jinan, Jinan 250031, China

关键词：

糖尿病心肌病; 发病机制; 治疗; 沉默信息调节因子6; 综述;

Keywords：

Diabetic cardiomyopathy; Pathogenesis; Treatment; SIRT6; Review

CLC：

R 542.2

DOI：

10.12114/j.issn.1008-5971.2023.00.017

Funds：

山东省自然科学基金面上项目（ZR2020MH042）

摘要：

糖尿病心肌病（DCM）指由糖尿病引起的，不能用冠状动脉粥样硬化性心脏病、高血压心脏病、瓣膜性心脏病及其他心脏病变解释的心肌病变，其表现为舒张或收缩功能障碍，最终发展为心力衰竭，与糖尿病患者的高死亡率密切相关。DCM的发病机制复杂，尚缺少特异性治疗方法。沉默信息调节因子6(SIRT6)是新近发现的DCM的治疗靶点，其可广泛参与DNA修复、端粒维持、糖脂代谢、炎症反应等多种生理活动。本文主要综述了DCM的发病机制、治疗，并分析了SIRT6调控DCM的机制：减轻心肌纤维化和脂毒性、抗氧化应激和抗炎、调控线粒体功能，以期为DCM的治疗提供一定参考。

Abstract：

Diabetic cardiomyopathy (DCM) is caused by diabetes, which cannot be explained by coronary atherosclerotic heart disease, hypertensive heart disease, valvular heart disease and other heart diseases. It is characterized by diastolic or systolic dysfunction and eventually develops into heart failure, which is closely related to the high mortality of diabetic patients. The pathogenesis of DCM is complex, and there is still a lack of specific treatment. Silent information regulator 6 (SIRT6) is a newly discovered target for the treatment of DCM, which is widely involved in various physiological activities such as DNA repair, telomere maintenance, glycolipid metabolism, and inflammatory response. This paper mainly reviews the pathogenesis and treatment of DCM, and illustrates the mechanisms of SIRT6 regulating DCM: reducing myocardial fibrosis and lipotoxicity, anti-oxidative stress and anti-inflammation, and regulating mitochondrial function, in order to provide some references for the treatment of DCM

ReferenceList：